摘要
单纯疱疾病毒胸苷激酶基因（HerpesSimplexVirus－ThymidineKinase，HSV－tk），配合核苷酸类似物（NAS）GCV或ACV的基因治疗是目前肿瘤基因治疗领域中一种较有希望的治疗方法．反转录病毒和腺病毒介导的HSV－tk／NAS肿瘤基因治疗系统的建立，并运用该系统进行脑胶质瘤、垂体瘤、黑色素瘤的基因治疗离体细胞和动物试验，取得了显著的肿瘤杀伤作用，特别是腺病毒介导的脑胶质瘤基因治疗动物试验效果很显著，能够完全消除肿瘤．同时，还建立了反转录病毒以及腺病毒HSV－tk基因治疗的安全性检测体系，为基因治疗的临床试验提供了安全性保证．
Herpes simplex virus-thymidine kinase combined with NAS (ACV or GCV) is a promising system in gene therapy for tumors. Retrovirus and adenovirus mediated HSV-tk/NAS tumor gene therapy system have been established respectively. Those systems were applied to gene therapy for human and rat glioma, menaloma both in vitro and in vivo and significant tumor killing results were obtained. Especially in adenovirus mediated gene therapy for rat glioma, the tumor cells could be killed and disappeared completely. Besides, the safety assessments for retrovirus and adenovirus mediated gene therapy for tumors were accomplished respectively.
出处
《复旦学报（自然科学版）》
CAS
CSCD
北大核心
1998年第4期372-378,共7页
Journal of Fudan University：Natural Science
基金
上海市科技启明星资助
